As more drugs go subcutaneous, Phillips Medisize's director of Front-End Innovation, Tony Bedford, believes that high-dose biologics will become a prevalent choice for drugmakers.

From vaccines to personalized cancer therapies, scientists are studying the use of mRNA across many clinical applications. However, there are several factors that are unique to mRNA drug product ...

The new liquid formulation of Rotarix does not require reconstitution or dilution before use. The Food and Drug Administration (FDA) has approved an oral-dosing applicator-only presentation (liquid ...

Stability is a critical factor in drug formulation, with implications for product quality, lifecycle management, and ...